Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
64Cu-GRIP B in Metastatic Renal Cell Carcinoma: NCT05888532 Clinical Landscape Report 2026
9 min read
64Cu-GRIP B in Metastatic Renal Cell Carcinoma: NCT05888532 Clinical Landscape Report 2026
16 October 2026
NCT05888532 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Epcoritamab in High grade B-cell lymphoma: ACTRN12623000620628 Clinical Landscape Report 2026
9 min read
Epcoritamab in High grade B-cell lymphoma: ACTRN12623000620628 Clinical Landscape Report 2026
16 October 2026
ACTRN12623000620628 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
Read →
ABM-1310 in Glioblastoma: NCT05892653 Clinical Landscape Report 2026
9 min read
ABM-1310 in Glioblastoma: NCT05892653 Clinical Landscape Report 2026
16 October 2026
NCT05892653 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Balstilimab in Relapsing classical Hodgkin lymphoma: NCT05891821 Clinical Landscape Report 2026
9 min read
Balstilimab in Relapsing classical Hodgkin lymphoma: NCT05891821 Clinical Landscape Report 2026
16 October 2026
NCT05891821 clinical landscape for Relapsing classical Hodgkin lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Obinutuzumab in Diffuse Large B-Cell Lymphoma: NCT05896163 Clinical Landscape Report 2026
9 min read
Obinutuzumab in Diffuse Large B-Cell Lymphoma: NCT05896163 Clinical Landscape Report 2026
16 October 2026
NCT05896163 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Daratumumab in Plasmablastic Lymphoma: NCT05907759 Clinical Landscape Report 2026
9 min read
Daratumumab in Plasmablastic Lymphoma: NCT05907759 Clinical Landscape Report 2026
16 October 2026
NCT05907759 clinical landscape for Plasmablastic Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fulvestrant in Ovarian Cancer: NCT05905341 Clinical Landscape Report 2026
9 min read
Fulvestrant in Ovarian Cancer: NCT05905341 Clinical Landscape Report 2026
16 October 2026
NCT05905341 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bevacizumab biosimilar(Jiangsu Hengrui Pharmaceuticals Co., Ltd.) in Triple Negative Breast Cancer: NCT05909332 Clinical Landscape Report 2026
9 min read
Bevacizumab biosimilar(Jiangsu Hengrui Pharmaceuticals Co., Ltd.) in Triple Negative Breast Cancer: NCT05909332 Clinical Landscape Report 2026
16 October 2026
NCT05909332 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Carboplatin in Glioblastoma Multiforme: NCT05902169 Clinical Landscape Report 2026
9 min read
Carboplatin in Glioblastoma Multiforme: NCT05902169 Clinical Landscape Report 2026
16 October 2026
NCT05902169 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Orvanesib in Uterine Carcinosarcoma: NCT05902988 Clinical Landscape Report 2026
9 min read
Orvanesib in Uterine Carcinosarcoma: NCT05902988 Clinical Landscape Report 2026
16 October 2026
NCT05902988 clinical landscape for Uterine Carcinosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ipilimumab in Microsatellite instability-high colorectal cancer: NCT05909995 Clinical Landscape Report 2026
9 min read
Ipilimumab in Microsatellite instability-high colorectal cancer: NCT05909995 Clinical Landscape Report 2026
16 October 2026
NCT05909995 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
Read →
Lomustine in Glioblastoma: NCT05904119 Clinical Landscape Report 2026
9 min read
Lomustine in Glioblastoma: NCT05904119 Clinical Landscape Report 2026
16 October 2026
NCT05904119 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →